IDEAYA Biosciences' Updates From key Early Oncology Programs are Supportive, RBC Says

MT Newswires Live11-17

IDEAYA Biosciences' (IDYA) updates from its key early oncology pipeline are supportive, and the strategy is shaping up well around rational combination opportunities, RBC Capital Markets said in a research report emailed Tuesday.

The company's IDE892 candidate showed a favorable safety profile and could be the most efficacious in combination regimens, the brokerage said, adding that it maintained its 2035 revenue guidance for the drug at $1.1 billion.

The company reaffirmed high expectations for the IDE892 and IDE397 regimen amid ongoing dose escalation, with potential expansion in H1 2027 in methylthioadenosine phosphorylase-deletions non-small cell lung cancer, according to the note.

The company's IDE101 and IDE574 candidates were portrayed as complementary approaches to targeting KRAS-driven tumors, analysts wrote.

The brokerage maintained its outperform rating on the stock and price target of $45 per share.

Price: 27.03, Change: -3.33, Percent Change: -10.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment